Combinatorial therapy using RNAi and curcumin nano-architectures regresses tumors in breast and colon cancer models

Nanoscale ◽  
2022 ◽  
Author(s):  
Aviral Kumar ◽  
Amarnath Singam ◽  
Guruprasadh Swaminathan ◽  
Naresh Killi ◽  
Naveen Kumar Tangudu ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Colorectal Cancers ◽  
Murine Models ◽  
Combinatorial Therapy ◽  
Cancer Models ◽  
S 100 ◽  
Eudragit S 100

This novel combination of curcumin (CU)–chitosan (CS) nanocomposites conjugated to Ephb4 shRNA encapsulated with Eudragit S-100 (ES) has been developed to combat breast and colorectal cancers murine models.

Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer

2010 ◽  
Vol 21 (9) ◽  
pp. 2691-2699 ◽  
Author(s):  
Naveen K. Thakral ◽  
Alok R. Ray ◽  
Dipak K. Majumdar
Keyword(s):  
Colon Cancer ◽  
Chitosan Microspheres ◽  
S 100 ◽  
Eudragit S 100

scholarly journals Eudragit S-100 coated sodium alginate microspheres of naproxen sodium: Formulation, optimization and in vitro evaluation / Alginatne mikrosfere naproksen natrija obložene Eudragitom S-100: Priprava, optimizacija i in vitro vrednovanje

2012 ◽  
Vol 62 (4) ◽  
pp. 529-545 ◽  
Author(s):  
Anuj Chawla ◽  
Pooja Sharma ◽  
Pravin Pawar
Keyword(s):  
Drug Release ◽  
Sodium Alginate ◽  
Naproxen Sodium ◽  
Drug Loading ◽  
Size Analysis ◽  
Scanning Calorimetry ◽  
Sem Images ◽  
S 100 ◽  
Eudragit S 100

The aim of the study was to prepare site specific drug delivery of naproxen sodium using sodium alginate and Eudragit S-100 as a mucoadhesive and pH-sensitive polymer, respectively. Core microspheres of alginate were prepared by a modified emulsification method followed by cross-linking with CaCl2, which was further coated with the pH dependent polymer Eudragit S-100 (2.5 or 5 %) to prevent drug release in the upper gastrointestinal environment. Microspheres were characterized by FT-IR spectroscopy, X-ray diffraction, differential scanning calorimetry and evaluated by scanning electron microscopy, particle size analysis, drug loading efficiency, in vitro mucoadhesive time study and in vitro drug release study in different simulated gastric fluids. Stability studies of the optimized formulation were carried out for 6 months. SEM images revealed that the surface morphology was rough and smooth for core and coated microspheres, respectively. Core microspheres showed better mucoadhesion compared to coated microspheres when applied to the mucosal surface of freshly excised goat colon. The optimized batch of core microspheres and coated microspheres exhibited 98.42 ± 0.96 and 95.58 ± 0.74 % drug release, respectively. Drug release from all sodium alginate microsphere formulations followed Higuchi kinetics. Moreover, drug release from Eudragit S-100 coated microspheres followed the Korsmeyer-Peppas equation with a Fickian kinetics mechanism. Stability study suggested that the degradation rate constant of microspheres was minimal, indicating 2 years shelf life of the formulation.

Immobilization of Streptomyces olivaceoviridis E-86 xylanase on Eudragit S-100 for xylo-oligosaccharide production

2005 ◽  
Vol 40 (8) ◽  
pp. 2707-2714 ◽  
Author(s):  
Zhilu Ai ◽  
Zhengqiang Jiang ◽  
Lite Li ◽  
Wei Deng ◽  
Isao Kusakabe ◽  
...  
Keyword(s):  
S 100 ◽  
Streptomyces Olivaceoviridis ◽  
Eudragit S 100

scholarly journals Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer

2020 ◽  
Author(s):  
Sebastian Dwertmann Rico ◽  
Doris Höflmayer ◽  
Franziska Büscheck ◽  
David Dum ◽  
Andreas M. Luebke ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Mismatch Repair ◽  
Cancer Progression ◽  
Strong Association ◽  
Tumor Location ◽  
Colorectal Cancers ◽  
Mismatch Repair Deficiency ◽  
Repair Deficiency ◽  
Cancer Aggressiveness ◽  
Rectal Cancers

AbstractMucin 5AC (MUC5AC) is a secreted gel-forming mucin expressed by several epithelia. In the colon, MUC5AC is expressed in scattered normal epithelial cells but can be abundant in colorectal cancers. To clarify the relationship of MUC5AC expression with parameters of tumor aggressiveness and mismatch repair deficiency (dMMR) in colorectal cancer, a tissue microarray containing 1812 colorectal cancers was analyzed by immunohistochemistry. MUC5AC expression was found in 261 (15.7%) of 1,667 analyzable colorectal cancers. MUC5AC expression strongly depended on the tumor location and gradually decreased from proximal (27.4% of cecum cancers) to distal (10.6% of rectal cancers; p < 0.0001). MUC5AC expression was also strongly linked to dMMR. dMMR was found in 21.3% of 169 cancers with MUC5AC positivity but in only 4.6% of 1051 cancers without detectable MUC5AC expression (p < 0.0001). A multivariate analysis showed that dMMR status and tumor localization predicted MUC5AC expression independently (p < 0.0001 each). MUC5AC expression was unrelated to pT and pN status. This also applied to the subgroups of 1136 proficient MMR (pMMR) and of 84 dMMR cancers. The results of our study show a strong association of MUC5AC expression with proximal and dMMR colorectal cancers. However, MUC5AC expression is unrelated to colon cancer aggressiveness.

Inulin Coated Mn3O4 Nanocuboids Coupled with RNA Interference Reverse Intestinal Tumorigenesis in Apc Knockout Murine Colon Cancer Models

2021 ◽  
pp. 102504
Author(s):  
Khushboo Kourani ◽  
Poonam Jain ◽  
Aviral Kumar ◽  
Ashok Kumar Jangid ◽  
Guruprasadh Swaminathan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Rna Interference ◽  
Intestinal Tumorigenesis ◽  
Cancer Models ◽  
Murine Colon

Formulation and Evaluation of Mucoadhesive Floating Microspheres of Repaglinide

2021 ◽  
pp. 5673-5679
Author(s):  
S. Sivaprasad ◽  
V. Alagarsamy ◽  
M. Prathibha Bharathi ◽  
P.V. Murali Krishna ◽  
K. Sandeeep Kanna
Keyword(s):  
Controlled Release ◽  
Release Kinetics ◽  
In Vitro Release ◽  
Extended Period ◽  
Entrapment Efficiency ◽  
Sustain Release ◽  
S 100 ◽  
Eudragit S 100 ◽  
Good Flow

The main objective of the present study was to design a controlled release dosage form for an oral anti diabetic drug i.e. repaglinide employing polymers like eudragit s- 100. One of the other objective of this present study was to increase the biological half-life the drug by formulating into microspheres. The microspheres of repaglinide were prepared by solvent evaporation method by using eudragit s-100 and ethyl cellulose as polymers with different concentrations. Formulations (F1-F10) were prepared and evaluated for various micrometric properties and it was observed that though all the formulations were exhibited good flow properties, The F5 formulation exhibits higher in- vitro buoyancy time and entrapment efficiency which is considered for in- vitro and mucoadhesive studies. The FTIR results reveal that there was no interaction between the drug and the excipients. The in- vitro release profiles of F1-F5 indicated that all formulations showed controlled release over an extended period, with acceptable release kinetics. Among the all formulations F5 were considered as a promising candidate for sustain release of repaglinide.

Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models

2019 ◽  
Vol 160 ◽  
pp. 110-120 ◽  
Author(s):  
Hye Yeon Jang ◽  
Do Hyung Kim ◽  
Haeng Jung Lee ◽  
Won Dong Kim ◽  
Seog-Young Kim ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Synergistic Effects ◽  
Cancer Models ◽  
Braf Mutant
Sign in / Sign up

Export Citation Format

Share Document